TNF and rheumatoid arthritis: In particular, RA patients have autoimmune dysfunction, and the use of JAK inhibitors (compared with TNF-α inhibitors) will increase the risk of infection, major adverse cardiovascular events (MACE), and thrombosis in RA patients27.